Pfizer : PFE

All Pfizer Articles

1490 Articles

Paul Ausick | Dec 2, 2015 at 4:01 PM EST

The 4 Stocks That Sank the DJIA on Wednesday

December 2, 2015: Markets opened mixed on Wednesday and only the Nasdaq Composite was able to remain in positive territory…

Paul Ausick | Dec 1, 2015 at 4:01 PM EST

The 4 Stocks That Lifted the Dow on Tuesday

December 1, 2015: Markets opened higher on again on Tuesday and, unlike yesterday, held on to the gains for the…

Paul Ausick | Nov 25, 2015 at 4:01 PM EST

The 4 Stocks That Lifted the Dow on Wednesday

ThinkstockNovember 25, 2015: Markets opened higher on Wednesday on a trading day when light volume is expected ahead of tomorrow’s…

Jon C. Ogg | Nov 25, 2015 at 8:42 AM EST

Top Analyst Upgrades and Downgrades: AmEx, Carnival, eBay, HP, IAMGOLD, Pfizer, Tech Data and Many More

Stocks were indicated surprisingly higher after international markets recovered more than might have been expected. The trend that has been…

Paul Ausick | Nov 24, 2015 at 4:01 PM EST

The 4 Stocks That Buoyed the DJIA on Tuesday

November 24, 2015: Markets opened lower on Tuesday following reports that a Turkish plane had shot down a Russian plane…

Lee Jackson | Nov 24, 2015 at 10:47 AM EST

Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016

Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the…

Paul Ausick | Nov 23, 2015 at 4:01 PM EST

The 4 Stocks That Weighed on the Dow Monday

November 23, 2015: Markets opened mixed on Monday with very slight positive or negative differences from Friday’s closing prices. The…

Lee Jackson | Nov 20, 2015 at 9:35 AM EST

4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming

A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near…

Chris Lange | Nov 18, 2015 at 9:10 AM EST

Jefferies Reveals Top 5 Pharma Stock Picks for Growth and Dividends

Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks

Chris Lange | Nov 11, 2015 at 8:15 AM EST

Short Sellers Continue to Decrease Bets in Major Pharma

The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical…

Paul Ausick | Nov 4, 2015 at 4:01 PM EST

The 4 Stocks Held Down the DJIA on Wednesday

November 4, 2015: Markets opened higher on Wednesday following an in-line report on jobs from ADP and somewhat smaller-than-expected U.S.…

Lee Jackson | Nov 4, 2015 at 10:40 AM EST

UBS Has 4 Safe Blue Chip Dividends to Buy, Even If the Market Has Topped

Solid growth stocks that pay good dividends make sense, especially when they all pay higher dividends than the current 30-year…

Chris Lange | Nov 3, 2015 at 11:45 AM EST

Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger

The health care sector may have sold off a fair amount since this past summer, but there is some M&A…

Paul Ausick | Nov 2, 2015 at 4:01 PM EST

The 4 Stocks Lifted the DJIA on Monday

November 2, 2015: Markets opened higher on Monday and added strength as the day drew to a close. Healthcare and…

Chris Lange | Oct 31, 2015 at 10:10 AM EDT

6 BioPharma Movers That Cannot Be Ignored

Last week, a few biotech companies made absolutely massive runs, and some had serious falls.

1 … 55 56 57 58 59 … 100

Pfizer : PFE

All Pfizer Articles

The 4 Stocks That Sank the DJIA on Wednesday

The 4 Stocks That Lifted the Dow on Tuesday

The 4 Stocks That Lifted the Dow on Wednesday

Top Analyst Upgrades and Downgrades: AmEx, Carnival, eBay, HP, IAMGOLD, Pfizer, Tech Data and Many More

The 4 Stocks That Buoyed the DJIA on Tuesday

Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016

The 4 Stocks That Weighed on the Dow Monday

4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming

Jefferies Reveals Top 5 Pharma Stock Picks for Growth and Dividends

Short Sellers Continue to Decrease Bets in Major Pharma

The 4 Stocks Held Down the DJIA on Wednesday

UBS Has 4 Safe Blue Chip Dividends to Buy, Even If the Market Has Topped

Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger

The 4 Stocks Lifted the DJIA on Monday

6 BioPharma Movers That Cannot Be Ignored

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

3 Stocks With a Yield Over 6% For Passive Income Investors

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

A $2.5 Million 401(k) at 73 Can Still Cost You Six Figures Without These 3 Moves

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

Pfizer : PFE

All Pfizer Articles

The 4 Stocks That Sank the DJIA on Wednesday

The 4 Stocks That Lifted the Dow on Tuesday

The 4 Stocks That Lifted the Dow on Wednesday

Top Analyst Upgrades and Downgrades: AmEx, Carnival, eBay, HP, IAMGOLD, Pfizer, Tech Data and Many More

The 4 Stocks That Buoyed the DJIA on Tuesday

Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016

The 4 Stocks That Weighed on the Dow Monday

4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming

Jefferies Reveals Top 5 Pharma Stock Picks for Growth and Dividends

Short Sellers Continue to Decrease Bets in Major Pharma

The 4 Stocks Held Down the DJIA on Wednesday

UBS Has 4 Safe Blue Chip Dividends to Buy, Even If the Market Has Topped

Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger

The 4 Stocks Lifted the DJIA on Monday

6 BioPharma Movers That Cannot Be Ignored

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

3 Stocks With a Yield Over 6% For Passive Income Investors

Featured Reads

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

A $2.5 Million 401(k) at 73 Can Still Cost You Six Figures Without These 3 Moves